देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
IMMUNOGLOBULIN (HUMAN)
TAKEDA CANADA INC
J06BA02
IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASC. ADM.
10%
SOLUTION
IMMUNOGLOBULIN (HUMAN) 10%
INTRAVENOUS
10/25/50/100/200/300ML
Schedule D
SERUMS
Active ingredient group (AIG) number: 0106267005; AHFS:
APPROVED
2018-05-04
_ _ _ _ _Page 1 of 56_ PRODUCT MONOGRAPH GAMMAGARD LIQUID ® Immunoglobulin Intravenous (Human), [IGIV] 10% Solution for infusion and 1 g/10 mL, 2.5 g/25 mL, 5 g/50 mL, 10 g/100 mL, 20 g/200 mL, 30 g/300mL Pharmacopeial Replacement Therapy for Immunodeficiencies Takeda Canada Inc. 22 Adelaide Street West, Suite 3800 Toronto Ontario M5H 4E3 Submission Control No: 256703 Date of Initial Approval: April 12, 2006 Date of Revision: November 26, 2021 GAMMAGARD ® and GAMMAGARD LIQUID ® are registered trademarks of Baxalta Incorporated. Takeda TM and the Takeda Logo ® are trademarks of Takeda Pharmaceutical Company Limited, used under license. _ _ _ _ _Page 2 of 56_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 DESCRIPTION ........................................................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................ 4 CONTRAINDICATIONS ............................................................................................ 5 WARNINGS AND PRECAUTIONS ............................................................................ 6 ADVERSE REACTIONS............................................................................................11 DRUG INTERACTIONS ............................................................................................15 DOSAGE AND ADMINISTRATION .........................................................................16 OVERDOSAGE .........................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY.........................................................18 STORAGE AND STABILITY ....................................................................................21 SPECIAL HANDLING INSTRUCTIONS ............................................... पूरा दस्तावेज़ पढ़ें